UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 170

Sortiert nach

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease

Scientific reports, 2020-06, Vol.10 (1), p.9330-9330, Article 9330

2020

Volltextzugriff (PDF)

Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet

BMC cancer, 2023-01, Vol.23 (1), p.59-59, Article 59

2023

Volltextzugriff (PDF)

Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress

Drug development research, 2021-09, Vol.82 (6), p.852-860

2021

Volltextzugriff (PDF)

Comparison of different QT correction methods for nonclinical safety assessment in ketamine-anesthetized Indian rhesus monkeys (Macaca mulatta)

Toxicology mechanisms and methods, 2023-07, Vol.33 (6), p.490-501

2023

Volltextzugriff (PDF)

Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases

Journal of medicinal chemistry, 2018-08, Vol.61 (16), p.6964-6982

2018

Volltextzugriff (PDF)

Effect of GLP-1 based therapies on diabetic dyslipidemia

Current diabetes reviews, 2014-01, Vol.10 (4), p.238

2014

Volltextzugriff (PDF)

Hematological and biochemical reference intervals of wild-caught and inhouse adult Indian rhesus macaques (Macaca mulatta)

Laboratory Animal Research, 2022, 38(4), , pp.302-310

2022

Volltextzugriff (PDF)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

Liver international, 2018-06, Vol.38 (6), p.1084-1094

2018

Volltextzugriff (PDF)

Synthesis and antidiabetic activity of 2,5-disubstituted-3-imidazol-2-yl-pyrrolo[2,3- b]pyridines and thieno[2,3- b]pyridines

Bioorganic & medicinal chemistry, 2007-11, Vol.15 (21), p.6782-6795

2007

Volltextzugriff (PDF)

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state

Current research in pharmacology and drug discovery, 2022, Vol.3, p.100102-100102, Article 100102

2022

Volltextzugriff (PDF)

The Perspective of Using Flow Cytometry for Unpuzzling Hypoxia-Inducible Factors Signalling

Drug research, 2024-03, Vol.74 (3), p.113

2024

Volltextzugriff (PDF)

Design, synthesis, and biological evaluation of substituted- N-(thieno[2,3- b]pyridin-3-yl)-guanidines, N-(1 H-pyrrolo[2,3- b]pyridin-3-yl)-guanidines, and N-(1 H-indol-3-yl)-guanidines

Bioorganic & medicinal chemistry, 2007-05, Vol.15 (9), p.3248-3265

2007

Volltextzugriff (PDF)

Efficient Synthesis of Unsymmetrical Dibenzothiophenes by Acid-Mediated Intramolecular Cyclization of Biaryl Methyl Sulfoxides

Synthetic communications, 2012-02, Vol.42 (4), p.497-505

2012

Volltextzugriff (PDF)

Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor

Bioorganic & medicinal chemistry letters, 2020-11, Vol.30 (21), p.127571-127571, Article 127571

2020

Volltextzugriff (PDF)

Simultaneous determination of sacubitrilat and fimasartan in rat plasma by a triple quad liquid chromatography–tandem mass spectrometry method utilizing electrospray ionization in positive mode

Biomedical chromatography, 2021-02, Vol.35 (2), p.e4981-n/a

2021

Volltextzugriff (PDF)

HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia

Toxicology and applied pharmacology, 2024-02, Vol.483, p.116832-116832, Article 116832

2024

Volltextzugriff (PDF)

An insight into the presence of impurities in reference standards and their impact on mass spectrometry-based bioanalysis

Bioanalysis, 2022-09, Vol.14 (18), p.1191-1195

2022

Volltextzugriff (PDF)

ZYKR1, a novel, potent, and peripherally selective kappa opioid receptor agonist reduces visceral pain and pruritus in animal models

European journal of pharmacology, 2022-06, Vol.924, p.174961, Article 174961

2022

Volltextzugriff (PDF)

Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes

Bioorganic & medicinal chemistry, 2021-04, Vol.35, p.116071-116071, Article 116071

2021

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects

Clinical drug investigation, 2013-11, Vol.33 (11), p.809-816

2013

Volltextzugriff (PDF)

Effect of fasting duration on clinical pathology results in Wistar rats

Veterinary clinical pathology, 2009-09, Vol.38 (3), p.361-366

2009

Volltextzugriff (PDF)

Immunization of laboratory animal workers: occupational health and safety aspects

Pathogens and global health, 2024-03, p.1-21

2024

Volltextzugriff (PDF)

Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers

Clinical pharmacokinetics, 2018-01, Vol.57 (1), p.87-102

2018

Volltextzugriff (PDF)

Therapeutic potential of coagonists of glucagon and GLP-1

Cardiovascular & hematological agents in medicinal chemistry, 2014-01, Vol.12 (2), p.126

2014

Volltextzugriff (PDF)

Safety Assessment of a Novel Intravenous Diclofenac Sodium Formulation Following 28-Day Repeated Administration in Wistar Rats

International journal of toxicology, 2024-06, p.10915818241261922

2024

Volltextzugriff (PDF)

1 – 25 von 170

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(148)
Mit Volltextzugriff
(155)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease

Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet

Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress

Comparison of different QT correction methods for nonclinical safety assessment in ketamine-anesthetized Indian rhesus monkeys (Macaca mulatta)

Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases

Effect of GLP-1 based therapies on diabetic dyslipidemia

Hematological and biochemical reference intervals of wild-caught and inhouse adult Indian rhesus macaques (Macaca mulatta)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

Synthesis and antidiabetic activity of 2,5-disubstituted-3-imidazol-2-yl-pyrrolo[2,3- b]pyridines and thieno[2,3- b]pyridines

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state

The Perspective of Using Flow Cytometry for Unpuzzling Hypoxia-Inducible Factors Signalling

Design, synthesis, and biological evaluation of substituted- N-(thieno[2,3- b]pyridin-3-yl)-guanidines, N-(1 H-pyrrolo[2,3- b]pyridin-3-yl)-guanidines, and N-(1 H-indol-3-yl)-guanidines

Efficient Synthesis of Unsymmetrical Dibenzothiophenes by Acid-Mediated Intramolecular Cyclization of Biaryl Methyl Sulfoxides

Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor

Simultaneous determination of sacubitrilat and fimasartan in rat plasma by a triple quad liquid chromatography–tandem mass spectrometry method utilizing electrospray ionization in positive mode

HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia

An insight into the presence of impurities in reference standards and their impact on mass spectrometry-based bioanalysis

ZYKR1, a novel, potent, and peripherally selective kappa opioid receptor agonist reduces visceral pain and pruritus in animal models

Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes

Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects

Effect of fasting duration on clinical pathology results in Wistar rats

Immunization of laboratory animal workers: occupational health and safety aspects

Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers

Therapeutic potential of coagonists of glucagon and GLP-1

Safety Assessment of a Novel Intravenous Diclofenac Sodium Formulation Following 28-Day Repeated Administration in Wistar Rats

Suchergebnisse filtern